Company Encyclopedia
View More
name
EDAP TMS
EDAP.US
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services.
1.407 T
EDAP.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking87/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-59.52%E
    • Profit Margin-30.77%E
    • Gross Margin43.02%B
  • Growth ScoreC
    • Revenue YoY2.86%C
    • Net Profit YoY9.28%C
    • Total Assets YoY-18.33%E
    • Net Assets YoY-42.56%E
  • Cash ScoreD
    • Cash Flow Margin-325.00%D
    • OCF YoY2.86%C
  • Operating ScoreA
    • Turnover0.91A
  • Debt ScoreD
    • Gearing Ratio62.06%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Edap Tms (NASDAQ:EDAP) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

    Edap Tms (NASDAQ:EDAP) stock price crossed above its 200-day moving average, trading as high as $2.34. The stock has a consensus 'Hold' rating with a price target of $8.50. Recent earnings showed a smaller-than-expected loss, and institutional investors have been adjusting their positions. The company focuses on minimally invasive medical devices for urological diseases.

    Market Beat·
    US
    EDAP
    -0.62%
    Market Beat·
    US
    EDAP
    -0.62%

    EDAP TMS SA Receives FDA 510(k) Clearance for Enhanced Focal One Robotic HIFU System

    Edap TMS SA has received FDA 510(k) clearance for enhancements to its Focal One HIFU system, including advanced imaging and workflow improvements. This approval strengthens its position in robotic focal therapy for prostate cancer.

    Reuters·
    US
    EDAP
    -0.62%
    Reuters·
    US
    EDAP
    -0.62%

    Edap TMS SA to Present at Piper Sandler 37th Annual Healthcare Conference

    Edap TMS SA will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. CEO Ryan Rhodes will participate in a fireside discussion, and along with CFO Ken Mobeck, will host one-on-one investor meetings. The original content was published by Edap TMS SA via GlobeNewswire on November 18, 2025.

    Reuters·
    US
    EDAP
    -0.62%
    Reuters·
    US
    EDAP
    -0.62%

    EDAP TMS Highlights Growth in Prostate Cancer Treatment with Focal One HIFU

    EDAP TMS announced a report on November 18, 2025, highlighting the market potential of its Focal One HIFU technology for prostate cancer treatment. The company emphasized strong clinical evidence and superior outcomes compared to traditional methods, aiming to expand its presence in the global market. Analysts rate EDAP stock as Hold with a $2.00 price target, noting financial challenges despite strategic advancements. EDAP TMS is a leader in therapeutic ultrasound, focusing on cancer treatment.

    Tip Ranks·
    US
    EDAP
    -0.62%
    Tip Ranks·
    US
    EDAP
    -0.62%

    European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

    European equities traded in the US as American depositary receipts declined 0.93% on Friday, reaching 1,612.91 on the S&P Europe Select ADR Index. Ascendis Pharma and Cellectis led gainers from continental Europe, while EDAP TMS and Materialise led decliners. In the UK and Ireland, Akari Therapeutics and Autolus Therapeutics were top gainers, while NuCana and Endava were top decliners. The index is up 0.57% for the week.

    fidelity·
    US
    EDAP
    -0.62%
    US
    MTLS
    -1.32%
    fidelity·
    US
    EDAP
    -0.62%
    US
    MTLS
    -1.32%
    © 2025 Longbridge｜Disclaimer